Angiocrine Bioscience Announces First Patient Dosed in Pivotal Phase 3 Clinical Trial of AB-205 in Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation (E-CELERATE) and Completion of Series B Financing
SAN DIEGO, March 29, 2022 /PRNewswire/ -- Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in its Phase 3 registration study AB-205-301 (E-CELERATE), a multi-center, randomized, double-blind, placebo-controlled study of AB-205 in adults with lymphoma undergoing high-dose chemotherapy (HDT) and autologous hematopoietic cell transplantation (AHCT). AB-205 is an intravenous investigational engineered cell therapy product being developed for multiple indications.
E-CELERATE has been designed to evaluate the efficacy and safety of AB-205 as a treatment for damaged organ vascular stem cell niches caused by off-target cytotoxicity of HDT and prevent the progression of severe multi-organ complications, which can be life threatening and prolong hospitalization. The US Food and Drug Administration has conferred special regulatory status to AB-205 via the Regenerative Medicine Advanced Therapy and Orphan Drug designations for this indication.
More information about the E-CELERATE trial and participating sites may be found at the National Institute of Health's ClinicalTrials.gov website - NCT05181540.
"We expect 2022 to be a transformational year at Angiocrine, and we are excited to initiate this pivotal Phase 3 study," said Paul Finnegan, MD, Angiocrine's CEO. "We look forward to continuing to work with many of the leading cancer centers in the United States as we advance into the final clinical stages of this exciting program."
Series B Financing
About Severe Toxicities and Complications during High-Dose Chemotherapy (HDT) and Autologous Hematopoietic Cell Transplant (AHCT)
About Angiocrine Bioscience, Inc.
For additional information, please contact:
View original content to download multimedia:https://www.prnewswire.com/news-releases/angiocrine-bioscience-announces-first-patient-dosed-in-pivotal-phase-3-clinical-trial-of-ab-205-in-patients-with-lymphoma-undergoing-autologous-hematopoietic-cell-transplantation-e-celerate-and-completion-of-series-b-financing-301511823.html
SOURCE Angiocrine Bioscience, Inc.